Global Information Inc. is pleased to announce a new IBC Asia Conference

Oct. 21, 2010 - PRLog -- Global Information Inc. is pleased to announce a new Conference, "21st Annual International Antibody Engineering" by IBC Asia.

Join top faculty members and network with professionals in the protein engineering field at this event located in San Diego, California. Gain insight on the latest technology in antibody engineering. Additionally, this event is co-located with IBCs 8th annual Antibody Therapeutics conference, which will occur from the 7th to the 9th of December.

The following topics will be covered by this years conference:

Deep Sequencing of Antibody Genes: Technology, Data Storage and Analysis (Pre-Conference Workshop on December 5, 2010)

•Neutralizing Antibodies and Identification of Vaccine Targets:

◦Protective Antibodies to Teach Vaccine Design
◦Dissecting the Role of Antibodies in Protection and Enhancement of Dengue Virus Infection in a Mouse Model of Dengue Disease
◦Antibodies in Treating Infectious Disease

•Twenty Years of Phage Display

◦Combinatorial Antibody Libraries from Patients with Acute Infection or Transplant Rejection Reveal the Good and Bad of Immunological Attack
◦Making Therapeutic Drugs by Phage Display: Combining Biology and Chemistry
◦Recombinant Antibodies in Research and Medicine
◦A Fireside Chat with the Pioneers of Phage Display

•Antibody Biosynthesis, Structure and Stability:

◦IgG Discovery and Fc Engineering in E.coli
◦IgGs from Glycoengineered Pichia Pastoris
◦How Framework Mutations Influence Antibody Biosynthesis in Mammalian, Yeast and Bacterial Cells
◦Understanding Conservation within Ig-domains and its Application to Antibody Engineering
◦How Antibodies Fold and Assemble
◦Inclonals; IgGs and IgG-enzyme-Fusion Proteins Produced in an E.coli Expression-Refolding System
◦Generation of Therapeutic Antibodies Against Inflammatory Disease and Cancer Targets with a Low Risk of Clinical Immunogenicity
◦Production and Epitope Mapping of Antibodies Targeting Membrane Proteins
◦Kinetics on Cells: Bridging the Gap between Traditional Biosensor and Cell Based Assay
◦Enhancing the Activities of Monoclonal Antibodies for Cancer Therapy

•Antibodies in a Complex Environment:

◦Long-lasting Antitumor Protection by Anti-CD20 Antibody through Cellular Adaptive Immune Response
◦In Silico Design and Investigation of Polyvalent Vaccines for T cell Epitopes in HIV Variants
◦Understanding the Role of Affinity in the Targeting of Solid Tumor Antigens
◦Antibodies for Specific Recognition of Structure RNA
◦Interfering Transbody: A New Gene-Silencing Technology Mediated by Antibody
◦Therapeutic Antibody Targeting of Individual Notch Receptors

•Antibody Half-Life: the Long and the Short of It:

◦FcRn as a Global Regulator of IgG Transport and Levels: From Subcellular Imaging to In Vivo Studies
◦Improved in Vivo Efficacy of Xtend Antibodies Fc-engineered to Extend Half-life
◦Tuning the Half-life of Protein Therapeutics by Fusion to XTEN
◦Fab-Fv: A Bispecific Antibody Fragment Format with Extended Serum Half-Life
◦Constructing Ultra Long Half-life Life Peptides and Proteins using AlbudAbs
◦Engineering Antibody Pharmacokinetics by Chemical Modification and by Gene Fusion: Preclinical and Clinical Results

•Targeted Nanoparticle Therapeutics:

◦Immunolposome-based Nanoparticle Agents for Cancer Treatment
◦Antibody Targeted Iron Oxide Nanoparticles for Cancer Imaging and Therapy
◦Nanoliposomes Targeted via Single-Chain Fv Fragments
◦Targeting B Lymphoma with Nanoparticles Bearing Glycan Ligands of CD22
◦A Novel Strategy for Sensitizing Cancer Cells
◦The Antibody Hinge Region as a Key Determinant to Modulate Intrinsic Activity and Effector Functions

•Renaissance of Bispecific Antibodies:
◦Bispecific T Cell Engager Blinatumomab for the Treatment of Patients with Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia
◦MM-111: A Novel Bispecific Inhibitor of the Erb B2/ErbB3 Oncogenic Unit
◦Bispecific TandAbs for Inducing Tumor Cell Lysis via T and NK cells
◦Multi-specific Adnectins: Realizing the Promise of a Novel Class of Targeted Biologics
◦CVS-241: A VEGF and Ang2 Targeting Bispecific CovX-Body
◦Potent Activity of Bispecific DART Proteins Directed to Solid Tumors and Cancer Stem Cells

•Antibody Engineering for Second- and Third-Generation Antibody Therapeutics; Lessons Learned from the First Generation:

◦Signaling and Immunomodulation: The Twin Pillars of Effective Antibody Therapy of Cancer
◦Insights on the Development of Herceptin, T-DMI and Pertuzumab
◦Antibodies as Oncology Drugs, Past, Present, and Future
◦Developments in Antigen-Targeted Imaging in Cancer
◦Developing Glycoengineered CD20 and EGFR Antibodies with Enhanced Effector Functions

Event Glance:

Conference: Antibody Engineering
Organizer: IBC USA
Dates: December 5-9, 2010
Venue: Hilton San Diego Bayfront Hotel
Location: San Diego, CA USA
Website: http://www.the-infoshop.com/conference/antibodyeng10/

Contact Us:
Telephone: +1-860-674-8796
Email: us-info@gii.co.jp or us-sales@gii.co.jp
Address: 195 Farmington Avenue, Suite 208  - Farmington, CT 06032 USA

# # #

Global Information, Inc. (GII) is an online aggregator of premium market research.

Contact us:
Toll Free (US & CANADA): +1-866-353-3335
Outside US: +1-860-674-8796